Synergix: Searching with software

Synergix Inc. sees the dilemma of genome-driven target overload as an opportunity to apply its rational drug design technology to rapidly create and optimize leads in a cost-effective manner.

Founded in 1996, Synergix evolved out of the work of founder and CEO Claude Cohen, who honed the technology for molecular modeling and drug design at Hoechst-Roussel-Uclaf-Marion and Ciba-Geigy Ltd., now Aventis

Read the full 601 word article

How to gain access

Continue reading with a
two-week free trial.